FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043282363> ?p ?o ?g. }

• W2043282363 endingPage "180" @default.
• W2043282363 startingPage "179" @default.
• W2043282363 abstract "One of the earliest articles testifying to the immunosuppressive potency of the cyclic fungal peptide cyclosporin appeared in this journal in 1979 [1]. Cyclosporin was widely adopted into clinical practice in the l980s, becoming the mainstay of anti-rejection therapy in organ transplantation and also being used to treat numerous autoimmune diseases. In the succeeding two decades, much has been learned about the mode of action of the drug: its major immunosuppressive action in T cells is via inhibition of specific transcription factors such as NF-AT and NF-IL2A which mediate cytokine gene transcription, especially that of IL-2. Cyclosporin forms a complex with a cognate intracellular binding protein cyclophilin and inhibits its peptidyl-prolyl cis-trans isomerase activity. This leads to blockade of the Ca2+/ca1modulin-regulated phosphatase calcineurin which is involved in activation of the transcription factors [2].More recently, several newer immunosuppressive agents have become available, including tacrolimus, which has a similar mode of action to cyclosporin [3]. Unfortunately, it has become apparent that the adverse effects of cyclosporin and tacrolimus include nephrotoxicity [4]. Thus, clinicians involved in kidney transplantation face the peculiar situation of trying to protect the kidney from rejection using a drug which itself is capable of inducing significant kidney damage.The introduction of cyclosporin was associated with a major improvement in early kidney transplant rejection rates and improved short-term graft survival [5], but disappointingly this has not been translated into improved long-term graft survival, and there is considerable concern that one reason for this may be that the drug's nephrotoxic effects negate its protective role. The adverse effects are dose-related and can be minimized to some extent by careful titration of dosage and blood levels, but nephrotoxicity remains a major limiting factor. The drug is also used in the treatment of many primary kidney diseases which are believed to be immune-mediated [6]; it seems particularly illogical to use a nephrotoxic drug in diseases where the main aim of therapy is to prevent nephron loss and preserve kidney function.So should we discard cyclosporin? Unfortunately there are few alternative agents and, as mentioned above, one of them, tacrolimus, has similar nephrotoxic effects. Therefore rational design of new drugs, aiming to divorce the immunosuppressive potency of cyclosporin from its nephrotoxic effects, will depend upon an understanding of how it exerts its good and bad effects on the kidney. Cyclosporin reduces renal blood flow acutely by causing vasoconstriction and in the longer term by a variety of mechanisms including intimal thickening in blood vessels, hypertension and hyperlipidaemia, and also leads to interstitial fibrosis in the kidney. The haemodynamic effects can be antagonized to some extent by vasodilators such as nifedipine [7]; anti-oxidants have also been reported to protect against cyclosporin-induced renal injury [8,9], the assumption being that deleterious oxygen-derived free radicals are released as a consequence of renal ischaemia.The typical histopathological feature of cyclosporin nephrotoxicity is interstitial fibrosis, and whilst this may simply be the end result of ischaemia, there is evidence that cyclosporin has other effects which promote the accumulation of collagen in the kidney [10]. Mediators of fibrosis include transforming growth factor-beta (TGF-β), and it is of considerable interest that production of this cytokine is ‘spared’ or even enhanced by both cyclosporin and tacrolimus [11,12]. Ironically, this could be both good and bad: good in the early stages since TGF-β may have immunosuppressive actions, but bad later on because of its potent pro-fibrotic effects. This point is well illustrated by a recent study which showed that cyclosporin's effects in vivo on lymphocyte proliferation and renal injury could be mimicked by TGF-β1 and abrogated by anti-TGF-β1 [13].Another possible mode of action of cyclosporin is proposed by Rincon et al. in this issue of Clinical and Experimental Immunology [14] in a study of adhesion molecule expression in a rat model of chronic serum sickness. Cyclosporin treatment was associated with impressive reduction in renal injury as judged by proteinuria, even though circulating antibody titres and the extent of complement C3 deposition in the glomeruli were not altered. Cyclosporin-treated animals showed marked reduction in expression of the adhesion molecules CD54, CD18 and CD1lb/c in the kidney, and substantial reduction in the extent of leucocyte infiltration. This study neatly illustrates some of the complexities of dissecting the modes of action of cyclosporin: the authors suggest that cyclosporin has a direct effect on adhesion molecule expression and thereby inhibits cellular infiltration, but the results could equally well be explained by inhibition of cytokine production by infiltrating and/or intrinsic renal cells, preventing up-regulation of adhesion molecule expression and amplification of inflammatory injury. Detailed time course studies in cyclosporin-treated and control animals would be required to determine which was the primary effect. Cyclosporin's ability to limit production of so many proinflammatory mediators, thereby interrupting the amplification of an inflammatory response, is one of the main reasons for the drug's potency; however, it also means that attempts to elucidate cyclosporin's mechanisms of action in vivo must be carefully designed to separate cause from consequence.As illustrated by the example of TGF-β1 discussed above, it may prove impossible to separate entirely the desired effects of cyclosporin from its undesired toxicities, but continued attempts to do so are essential if we are to design rational new therapeutic strategies and get away from the uncomfortable feeling that our drug therapy could be damaging the very organ we are trying to protect." @default.
• W2043282363 created "2016-06-24" @default.
• W2043282363 creator A5005200556 @default.
• W2043282363 date "2000-08-01" @default.
• W2043282363 modified "2023-10-16" @default.
• W2043282363 title "Cyclosporin: nephro-protective as well as nephrotoxic?" @default.
• W2043282363 cites W1970842110 @default.
• W2043282363 cites W1989232271 @default.
• W2043282363 cites W1998106772 @default.
• W2043282363 cites W2039705433 @default.
• W2043282363 cites W2042954145 @default.
• W2043282363 cites W2098173664 @default.
• W2043282363 cites W2116211819 @default.
• W2043282363 cites W2125985655 @default.
• W2043282363 cites W2137432394 @default.
• W2043282363 cites W2138045546 @default.
• W2043282363 cites W2164113870 @default.
• W2043282363 cites W2169429901 @default.
• W2043282363 cites W2333378480 @default.
• W2043282363 cites W4238428807 @default.
• W2043282363 cites W316589911 @default.
• W2043282363 doi "https://doi.org/10.1046/j.1365-2249.2000.01289.x" @default.
• W2043282363 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1905685" @default.
• W2043282363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10970156" @default.
• W2043282363 hasPublicationYear "2000" @default.
• W2043282363 type Work @default.
• W2043282363 sameAs 2043282363 @default.
• W2043282363 citedByCount "11" @default.
• W2043282363 crossrefType "journal-article" @default.
• W2043282363 hasAuthorship W2043282363A5005200556 @default.
• W2043282363 hasBestOaLocation W20432823632 @default.
• W2043282363 hasConcept C126189478 @default.
• W2043282363 hasConcept C126322002 @default.
• W2043282363 hasConcept C203014093 @default.
• W2043282363 hasConcept C2780091579 @default.
• W2043282363 hasConcept C71924100 @default.
• W2043282363 hasConceptScore W2043282363C126189478 @default.
• W2043282363 hasConceptScore W2043282363C126322002 @default.
• W2043282363 hasConceptScore W2043282363C203014093 @default.
• W2043282363 hasConceptScore W2043282363C2780091579 @default.
• W2043282363 hasConceptScore W2043282363C71924100 @default.
• W2043282363 hasIssue "2" @default.
• W2043282363 hasLocation W20432823631 @default.
• W2043282363 hasLocation W20432823632 @default.
• W2043282363 hasLocation W20432823633 @default.
• W2043282363 hasOpenAccess W2043282363 @default.
• W2043282363 hasPrimaryLocation W20432823631 @default.
• W2043282363 hasRelatedWork W2035930853 @default.
• W2043282363 hasRelatedWork W2039318446 @default.
• W2043282363 hasRelatedWork W2055112025 @default.
• W2043282363 hasRelatedWork W2080531066 @default.
• W2043282363 hasRelatedWork W2412396253 @default.
• W2043282363 hasRelatedWork W2419517467 @default.
• W2043282363 hasRelatedWork W2748952813 @default.
• W2043282363 hasRelatedWork W2899084033 @default.
• W2043282363 hasRelatedWork W3032375762 @default.
• W2043282363 hasRelatedWork W3108674512 @default.
• W2043282363 hasVolume "121" @default.
• W2043282363 isParatext "false" @default.
• W2043282363 isRetracted "false" @default.
• W2043282363 magId "2043282363" @default.
• W2043282363 workType "article" @default.